Biotech Breakthroughs THEME

1228.32 -15.5 (-1.26%) Sell

Optimize theme

BIOTECHBRKTHRU THEME investors incur serious losses

14 min read

Biotech Breakthroughs significantly underperformed today. It delivered -1.26% to close at 1228.32. During the last week it delivered -5.04% and saw a maximum drawdown of -5.04%.

[Theme constituents]

~BIOTECHBRKTHRU is currently in a bearish trend. The current bearish signal has generated a profit of +8.4% for investors in the last three months.

Trend

~BIOTECHBRKTHRU has been outperforming the SP500 index in recent time. It showed significant outperformance (compared to the SP500 index) from 26 Jan, 2017 to 19 Jul, 2018. Over the last 2 years 11 months and 14 days, ~BIOTECHBRKTHRU underperformed the SP500 index on 48% days. Which indicates that on days ~BIOTECHBRKTHRU underperforms the SP500 index, it's performance is marginally worse than on the days it outperforms the SP500 index.

During the last three months ~BIOTECHBRKTHRU was mostly loss making and delivered on average -0.21% per day. It's best return during this period (of +4.01%) was on Tuesday, 16 Oct, 2018. While it's worst loss in the same period (of -4.8%) was on Wednesday, 24 Oct, 2018. The longest stort-term trends during this period were 5 profitable and losing days. The bullish trend (which returned +4.15%) started on 30 Oct, 2018 and went on till 5 Nov, 2018 while the bearish trend (which returned -9.83%) started on 18 Oct, 2018 and went on till 24 Oct, 2018.

The last 12 months saw ~BIOTECHBRKTHRU's investors making profits in 8 months and incurring losses in 4 months. During the last year, ~BIOTECHBRKTHRU and SP500 index had the same number of profitable months. ~BIOTECHBRKTHRU was also a more risky investment than SP500 index as it's worst month in the last year, Oct 2018, returned -10.52% compared to -7.75% returned by SP500 index in Dec 2018. ~BIOTECHBRKTHRU and SP500 index, both had periods of 6 consecutive profitable months. It is interesting to note that both ~BIOTECHBRKTHRU and SP500 index significantly outperform during months when quarterly/annual results are announced.

Average investors who try to do a lot of trading will only make their brokers rich.
-- Michael Jenson

~BIOTECHBRKTHRU is currently seeing overall increase in volatility. In comparison, the SP500 index is seeing increase in volatility. During the last three months, there was a significant surge in ~BIOTECHBRKTHRU's volatility from 19 Sep, 2018 to 25 Oct, 2018. While there was a significant surge in the SP500 index's volatility from 19 Sep, 2018 to 29 Oct, 2018.

Advanced/professional short-term investors should note that ~BIOTECHBRKTHRU has significant positive skewness in it's return distribution. This indicates that investors can expect ~BIOTECHBRKTHRU to recover from drawdowns quickly. Which makes ~BIOTECHBRKTHRU a good candidate for investing on short-term bullish trends or even counter-trends hoping for a pull-back.

~BIOTECHBRKTHRU has more chance of extreme outcomes than the SP500 index. Therefore, ~BIOTECHBRKTHRU must receive a lower allocation than SP500 in your portfolio. SP500 index usually has shorter drawdown period than ~BIOTECHBRKTHRU.

Based on your interest in ~BIOTECHBRKTHRU you may find it interesting to know that AMRH, NSPR and AYTU have all shown remarkable performance and qualify to be on every investor's watchlist.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
Following
Symbol Price {{retType}} | Tr.
{{detail.symbol}} {{detail.close}} {{detail.priceChange}}  {{detail.pctChange}}%  {{detail.name}} {{detail.trend}} 
 
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter